RU2014121335A - Иммуногенное лечение рака - Google Patents

Иммуногенное лечение рака Download PDF

Info

Publication number
RU2014121335A
RU2014121335A RU2014121335A RU2014121335A RU2014121335A RU 2014121335 A RU2014121335 A RU 2014121335A RU 2014121335 A RU2014121335 A RU 2014121335A RU 2014121335 A RU2014121335 A RU 2014121335A RU 2014121335 A RU2014121335 A RU 2014121335A
Authority
RU
Russia
Prior art keywords
immunomodulator
cancer
therapy
paragraphs
tumor
Prior art date
Application number
RU2014121335A
Other languages
English (en)
Russian (ru)
Inventor
Чарльз ЭКЛ
Сатвиндер МУДАН
Джон ГРАНДЖ
Original Assignee
Иммодулон Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммодулон Терапьютикс Лимитед filed Critical Иммодулон Терапьютикс Лимитед
Publication of RU2014121335A publication Critical patent/RU2014121335A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2014121335A 2011-12-02 2012-12-03 Иммуногенное лечение рака RU2014121335A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1120779.2 2011-12-02
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (1)

Publication Number Publication Date
RU2014121335A true RU2014121335A (ru) 2016-01-27

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014121335A RU2014121335A (ru) 2011-12-02 2012-12-03 Иммуногенное лечение рака

Country Status (15)

Country Link
US (4) US20140356397A1 (enExample)
EP (1) EP2785361B1 (enExample)
JP (1) JP6085611B2 (enExample)
KR (1) KR20140097419A (enExample)
CN (1) CN104023733A (enExample)
AU (1) AU2012343536B2 (enExample)
BR (1) BR112014012880A2 (enExample)
CA (1) CA2857429A1 (enExample)
GB (1) GB201120779D0 (enExample)
IL (1) IL232890A0 (enExample)
IN (1) IN2014MN00955A (enExample)
MX (1) MX2014006511A (enExample)
RU (1) RU2014121335A (enExample)
SG (1) SG11201402396XA (enExample)
WO (1) WO2013079980A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
MX390311B (es) 2013-12-05 2025-03-20 Rfemb Holdings Llc Presentacion de antigeno de cancer mejorado a celulas que presentan por la descomposicion electrica de membrana por radiofrecuencia (rf-rmb) como un mecanismo adyuvante para la inmunoterapia.
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA2975123A1 (en) * 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
CA2990107A1 (en) * 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
TW202428236A (zh) 2016-01-15 2024-07-16 美商Rfemb控股有限公司 癌症之免疫治療
EP3442653A4 (en) * 2016-04-14 2020-02-26 Feldreich Caro Ruiz AB DEVICE FOR USE IN RADIATION THERAPY WITH AN IONIZING MODULE AND A UV LIGHT SOURCE
SG10202110763WA (en) 2017-03-28 2021-11-29 Emblation Ltd Stenosis treatment
CN111479571A (zh) 2017-07-21 2020-07-31 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
BR112021010799A2 (pt) 2018-12-03 2021-08-24 Fusion Pharmaceuticals Inc. Terapia combinada com radioimunoconjugados e inibidor do ponto de verificação
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
WO2021132636A1 (ja) * 2019-12-27 2021-07-01 特定非営利活動法人North East Japan Study Group がん治療方法及び医薬
WO2023007107A1 (en) * 2021-07-27 2023-02-02 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
JPH06501479A (ja) * 1990-11-08 1994-02-17 スタンフオード・ルツク・リミテツド 抗原担体
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
CA2369542C (en) 1999-04-23 2009-10-27 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
AU2006306521B2 (en) 2005-10-21 2011-12-22 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by TLR ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
WO2007112316A2 (en) * 2006-03-24 2007-10-04 Morton Donald L Mycobacterial immunotherapy for cancer treatment
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
AU2012225298B2 (en) * 2011-03-09 2017-05-11 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
EP2723381A4 (en) 2011-06-21 2015-03-18 Univ Johns Hopkins FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CA2990107A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
JP2021529741A (ja) 2018-06-25 2021-11-04 イモデュロン セラピューティクス リミテッド がん治療

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы

Also Published As

Publication number Publication date
KR20140097419A (ko) 2014-08-06
EP2785361B1 (en) 2018-11-28
US20200338181A1 (en) 2020-10-29
AU2012343536A1 (en) 2014-06-05
SG11201402396XA (en) 2014-10-30
WO2013079980A1 (en) 2013-06-06
MX2014006511A (es) 2014-12-05
CA2857429A1 (en) 2013-06-06
AU2012343536B2 (en) 2017-08-24
US11318193B2 (en) 2022-05-03
IL232890A0 (en) 2014-07-31
BR112014012880A2 (pt) 2017-06-13
CN104023733A (zh) 2014-09-03
US11554166B2 (en) 2023-01-17
US20190224294A1 (en) 2019-07-25
JP6085611B2 (ja) 2017-02-22
GB201120779D0 (en) 2012-01-11
US20140356397A1 (en) 2014-12-04
IN2014MN00955A (enExample) 2015-04-24
EP2785361A1 (en) 2014-10-08
NZ624994A (en) 2016-10-28
US20230149525A1 (en) 2023-05-18
JP2014533743A (ja) 2014-12-15

Similar Documents

Publication Publication Date Title
RU2014121335A (ru) Иммуногенное лечение рака
JP2014533743A5 (enExample)
Moskalik et al. The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd: YAG lasers
McCaughan Jr et al. Hematoporphyrin‐derivative and photoradiation therapy of malignant tumors
EA200501937A1 (ru) Способ лечения злокачественных опухолей
PH12015502260B1 (en) C. novyi for the treatment of solid tumors in humans
RU2015143106A (ru) Терапия злокачественных опухолей
CA2929284C (en) Apparatus for damaging cancerous cells utilizing radio frequency waves in heating with heating enhanced by infusion or injection of glucose
PT1276501E (pt) Metodo para o tratamento de tumores utilizando terapia fotodinamica
Ohyama et al. Laserthermia on head and neck malignancies—experimental and clinical studies
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
RU2466759C1 (ru) Способ лечения больных первичной меланомой кожи
Rivera et al. Minibeam spatially-fractionated radiation therapy is superior to uniform dose radiation therapy for abscopal effect when combined with PD-L1 checkpoint inhibitor immunotherapy in a dual tumor murine mammary carcinoma model
Stranadko et al. 24 PHOTODYNAMIC THERAPY FOR SKIN CANCER WITH CHLORIN DERIVATIVES UNDER THE OUTPATIENT CONDITIONS
JP2017202274A (ja) 遠赤外線がん温熱治療器
RU2004123049A (ru) Способ лучевого лечения больных злокачественными лимфомами
RU2617090C1 (ru) Способ фотодинамической терапии злокачественных опухолей
Kaplan et al. 23 PHOTODYNAMIC THERAPY IN COMBINED TREATMENT MODALITIES OF DISSEMINATED MELANOMA
Chung et al. Effect of photodynamic therapy in melanoma skin cancer cell line a375: In vivo study
CA2829719C (en) Focal photodynamic therapy methods
RU2286814C1 (ru) Способ лечения рака кожи и слизистых оболочек
RU2289455C1 (ru) Способ лечения метастазов
Gardner et al. Quantitative analysis of effect of neodymium-YAG laser on transplanted mouse carcinomas.
Kapinus et al. 22 PHOTODYNAMIC THERAPY OF LOCALLY INVASIVE CUTANEOUS CARCINOMA